drugset

drugset / Trial / NCT00471276

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

NCT00471276 ↗

Phase 2 Completed 83 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.

Timeline

Start: 2007-08
Primary completion: 2010-06
Completion: 2010-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	37.5 mg	—

Indications